This study provides a novel combination strategy for neoadjuvant therapy in ER+HER2− breast cancer, suggesting that iSBRT synergizes with ICI to reprogram the immune-cold tumor microenvironment, particularly beneficial for PD-L1-negative patients, offering critical evidence for the design of future clinical trials.
Literature Overview
The article titled 'Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2− breast cancer: a randomized phase 2 trial,' published in Nature Medicine, systematically investigates the efficacy and safety of combining immune-modulating stereotactic body radiotherapy (iSBRT) with immune checkpoint inhibitors (ICI) in high-risk, early-stage ER+HER2− breast cancer. Using a randomized controlled design, the study evaluated the pathological response rates of adding the anti-PD-L1 antibody durvalumab or the anti-CD73 antibody oleclumab to iSBRT plus chemotherapy. Although no significant difference in the primary endpoint was observed among the three groups, iSBRT combined with ICI significantly improved the pCR rate in PD-L1-negative patients, suggesting its potential to reverse immune-cold phenotypes. Further transcriptomic and paired biopsy analyses revealed dynamic reprogramming of the tumor microenvironment (TME), providing mechanistic insights into overcoming ICI resistance in the ER+HER2− subtype.Background Knowledge
ER+HER2− breast cancer accounts for approximately 70% of all breast cancer cases, among which the high-risk Luminal B-like subtype typically exhibits a pathologic complete response (pCR) rate below 20% to conventional neoadjuvant chemotherapy (NACT), indicating a significant unmet clinical need. This subtype often presents as an immune-cold tumor microenvironment (immune-cold TME), characterized by low TIL infiltration, low PD-L1 expression, and weak immunogenicity, resulting in extremely low response rates to PD-1/PD-L1 inhibitor monotherapy. The current challenge in immunotherapy for ER+HER2− breast cancer lies in effectively activating anti-tumor immune responses, especially in PD-L1-negative patients. Researchers propose that iSBRT can release tumor antigens and promote dendritic cell maturation via an in situ vaccine effect, thereby enhancing T-cell infiltration. Simultaneously, blocking the CD73-mediated adenosine signaling pathway can suppress the immunosuppressive microenvironment. Therefore, this study focuses on using iSBRT as an immune primer, combined with ICI to maintain T-cell activity, and explores whether CD73 inhibition can further enhance efficacy, particularly in traditionally refractory PD-L1-negative populations.
Research Methods and Experiments
The study employed a multicenter, randomized phase 2 trial design (Neo-CheckRay), enrolling 147 female patients with high-risk, early-stage ER+HER2− breast cancer, who were randomly assigned in a 1:1:1 ratio to three groups: NACT + iSBRT only (No_ICI), NACT + iSBRT + durvalumab (Single_ICI), or triple therapy (Double_ICI). The iSBRT regimen delivered 24 Gy in 3 fractions, precisely targeting the primary tumor while avoiding draining lymph nodes to preserve immune priming function. All patients received standard chemotherapy (paclitaxel + ddAC), with repeat biopsies performed one week after iSBRT in week 6 for dynamic biomarker analysis. The primary endpoint was the residual cancer burden (RCB 0/1) rate in the intent-to-treat (ITT) population, with secondary endpoints including pCR rate, safety, and biomarker changes. PD-L1 IC scores (VENTANA SP263) were centrally assessed and used for stratification, and high-risk patients were defined by MammaPrint gene expression profiling. Paired biopsy samples underwent IHC and bulk RNA sequencing to systematically analyze TME remodeling.Key Conclusions and Perspectives
Research Significance and Prospects
This study offers new insights into immunotherapy for ER+HER2− breast cancer: although this subtype has traditionally been considered unresponsive to ICI, iSBRT-induced in situ vaccine effects can convert 'cold' tumors into 'hot' ones, thereby enhancing the efficacy of anti-PD-L1 therapy. Notably, in PD-L1-negative patients, the pCR rate increased from 3.4% to 30%, far exceeding previous NACT+ICI trials (which achieved only +3.5–4.5%), suggesting that radiotherapy’s immune-modulating effects may overcome traditional biomarker limitations.
From a scientific perspective, this study underscores the importance of dynamic biomarker monitoring, as paired biopsies revealed a critical early window for TME remodeling, providing valuable resources for future mechanistic studies. Additionally, the reversal of MHC-I downregulation—a known immune escape mechanism—by iSBRT+ICI suggests its potential as a predictive biomarker.
Clinically, this strategy may improve breast-conserving surgery rates and reduce recurrence risk. Future efforts should focus on more precise patient selection (e.g., integrating TILs and MHC-I expression) and optimizing the sequencing of radiotherapy and ICI to maximize synergy. Although CD73 inhibition did not enhance efficacy, its dynamic expression retains predictive value, warranting further exploration of other adenosine pathway targets.
Conclusion
This study establishes iSBRT as a key immune-modulating tool in ER+HER2− breast cancer, significantly enhancing the efficacy of anti-PD-L1 therapy by reprogramming the immune-cold tumor microenvironment through localized radiotherapy, particularly achieving more than a threefold increase in pCR rates among PD-L1-negative patients. This finding challenges the limitations of PD-L1 as the sole biomarker and offers a potential chemotherapy-sparing or treatment-deescalation pathway for high-risk ER+HER2− patients. From bench to bedside, this study demonstrates the synergistic potential of multimodal therapy: radiotherapy is not only a local control modality but also a catalyst for systemic immune activation. Future research should focus on leveraging dynamic TME changes to guide personalized ICI application and explore combinations with other immune modulators (such as CD40 agonists or OX40) to further overcome response barriers. This work lays the foundation for precision immunotherapy in hormone receptor-positive breast cancer and is poised to reshape comprehensive management strategies for these patients.
